Rosalind Advisors, Inc. Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001622627
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2024 · 33 positions · Total reported value $107.02M · Top-10 concentration 58.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 54.8% · 9 new · 11 cut · 3 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): +4.7% · vs SPY +2.5% · Prev Value $269.06M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -5.8% · vs SPY -7.9% · Latest Value $244.66M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q1 2024 13F filing, Rosalind Advisors, Inc. disclosed 33 equity positions with a combined reported value of $107.02M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 58.3% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2024 were MYO ($8.00M), LYRA ($7.12M), MDWD ($6.93M). By sector, the heaviest allocations are Health Care 69.7%, Other 30.3%.
Versus the prior quarter, Rosalind Advisors, Inc. opened 9 new positions, trimmed 11 and fully exited 3, a turnover rate of 54.8% of positions. The portfolio's overlap with the prior quarter was 55% of names.
The largest new positions opened in Q1 2024 were CYBN ($5.77M), ABVX ($5.41M), CLSD ($3.97M).
Of the 3 positions fully exited versus the prior quarter, the largest were ATXS ($8.67M), SRPT ($6.37M), MDGL ($5.78M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2024)
Fully Exited (vs previous quarter)
- ATXS ASTRIA THERAPEUTICS INC · prev qtr: $8.67M
- SRPT SAREPTA THERAPEUTICS INC · prev qtr: $6.37M
- MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $5.78M
- ASND ASCENDIS PHARMA A/S · prev qtr: $2.12M
- NVNO ENVVENO MEDICAL CORPORATION · prev qtr: $1.60M
- RVPH REVIVA PHARMACEUTCLS HLDGS I · prev qtr: $1.01M
- MACK MERRIMACK PHARMACEUTICALS IN · prev qtr: $804.60K
Insider Transactions (Form 4)
Latest Rosalind Advisors, Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-13 | J | DELCATH SYSTEMS, INC. | 27,502 | — | SEC filing |
| 2026-10-13 | Conversion | DELCATH SYSTEMS, INC. | 3,627 | — | SEC filing |
Fund Profile
Rosalind Advisors, Inc. is an SEC-registered 13F filer. As of Q2 2026 it reported 33 US equity positions with a combined value of $269.06M. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Portfolio Structure
- 33 positions · $269.06M reported value (Q2 2026)
- Top 10 holdings = 74.1% of reported value
- Largest position: DCTH (DELCATH SYS INC) at 15.4%
- Average position size: $8.15M
Sector Tilt
- Health Care 94.7%
- Industrials 5.3%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 6 new, 7 added, 12 reduced, 8 exited
- 8 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.45M | $8.00M | 7.48% | Add | |
| 2 |
|
1.14M | $7.12M | 6.65% | Reduce | |
| 3 |
|
485.99K | $6.93M | 6.47% | Reduce | |
| 4 |
|
4.54M | $6.63M | 6.20% | Reduce | |
| 5 |
|
2.82M | $6.23M | 5.82% | Reduce | |
| 6 |
|
734.00K | $6.11M | 5.71% | Reduce | |
| 7 |
|
13.96M | $5.77M | 5.39% | New | |
| 8 |
|
378.42K | $5.41M | 5.06% | New | |
| 9 |
|
300.00K | $5.25M | 4.91% | Reduce | |
| 10 |
|
1.04M | $4.96M | 4.63% | Hold | |
| 11 |
|
533.33K | $4.55M | 4.25% | Hold | |
| 12 |
|
250.00K | $4.02M | 3.76% | Hold | |
| 13 |
|
2.59M | $3.97M | 3.71% | New | |
| 14 |
|
311.77K | $3.72M | 3.48% | New | |
| 15 |
|
287.99K | $3.42M | 3.19% | Reduce | |
| 16 |
|
926.02K | $3.19M | 2.98% | Reduce | |
| 17 |
|
4.50M | $3.15M | 2.94% | Add | |
| 18 |
|
1.88M | $2.59M | 2.42% | New | |
| 19 |
|
621.48K | $2.47M | 2.31% | Reduce | |
| 20 |
|
415.80K | $1.91M | 1.79% | New | |
| 21 |
|
686.06K | $1.63M | 1.52% | Reduce | |
| 22 |
|
2.30M | $1.62M | 1.52% | New | |
| 23 |
|
903.61K | $1.57M | 1.47% | New | |
| 24 |
|
1.55M | $1.41M | 1.32% | New | |
| 25 |
|
607.80K | $1.22M | 1.14% | Hold | |
| 26 |
|
1.51M | $1.19M | 1.11% | Reduce | |
| 27 |
|
758.97K | $781.74K | 0.73% | Hold | |
| 28 |
|
504.26K | $776.56K | 0.73% | New | |
| 29 |
|
200.00K | $660.00K | 0.62% | Hold | |
| 30 |
|
200.00K | $510.00K | 0.48% | New | |
| 31 |
|
900.90K | $167.57K | 0.16% | Hold | |
| 32 |
|
50.00K | $72.50K | 0.07% | Reduce | |
| 33 |
|
100.00K | $7.00K | 0.01% | Reduce | |
FAQ
What did Rosalind Advisors, Inc. buy in 2024-Q1?
In its 2024-Q1 13F filing, Rosalind Advisors, Inc. reported 33 equity positions worth $107.02M in aggregate; its largest disclosed positions were MYO ($8.00M), LYRA ($7.12M), MDWD ($6.93M).
How large is Rosalind Advisors, Inc.'s portfolio?
Rosalind Advisors, Inc. reported $107.02M of long equity holdings across 33 positions as of 2024-Q1. Top-10 holdings account for 58.3% of reported value.
What is Rosalind Advisors, Inc.'s investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.